Calprotectin in Bile

Voigtländer, Torsten; Wlecke, J; Negm, AA; Lenzen, Henrike; Manns, Michael P.; Lankisch, Tim O.

doi:10.1097/mcg.0000000000000042

Cited by 14 publications

(4 citation statements)

References 29 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…We found an additional weak positive correlation between plasma CRP concentrations and biliary calprotectin concentrations. In contrast to Voigtländer et al, 36 we detected no correlation between MRS and biliary calprotectin concentrations. Unfortunately, MRS determination was only possible retrospectively in 61 patients of our PSC cohort.…”

Section: Discussioncontrasting

confidence: 99%

“…Our observation that biliary calprotectin concentrations were higher in PSC patients than in controls confirms results from a study published by Voigtländer et al, 36 in which PSC patients without CCA displayed significantly higher biliary calprotectin concentrations than patients with choledocholithiasis. In their cohort of PSC patients, the median biliary calprotectin concentration was 237 mg/L, whereas it was 3.65 mg/L in our PSC cohort.…”

Section: Discussionsupporting

confidence: 92%

“…In our study, like in that by Voigtländer et al, 36 a weak positive correlation was established between plasma ALP concentrations and biliary calprotectin concentrations. We found an additional weak positive correlation between plasma CRP concentrations and biliary calprotectin concentrations.…”

Section: Discussionsupporting

confidence: 90%

“…In their study including 45 PSC patients, Reinhard et al 35 from our group demonstrated that the expression of S100A9 in bile was 2 times higher in PSC patients with high disease activity than in those with low disease activity. Voigtländer et al 36 showed in a study with 69 PSC patients that MRS and biliary calprotectin concentrations were correlated. Wang et al 37 published that S100A8 in bile may be a biomarker for gallbladder cancer.…”

Section: Introductionmentioning

confidence: 99%

See 3 more Smart Citations

Evaluation of Biliary Calprotectin as a Biomarker in Primary Sclerosing Cholangitis

Gauss

Sauer

Stiehl³

et al. 2016

Medicine

View full text Add to dashboard Cite

Primary sclerosing cholangitis (PSC) is a chronic inflammatory disease of the bile ducts with limited therapeutic options except liver transplantation. Reliable biomarkers to predict the disease course are unavailable, and currently employed disease activity scores such as the Mayo risk score (MRS) have limitations. The present study aims to evaluate biliary calprotectin as a marker of disease activity and prognosis in PSC.This is a monocentric retrospective observational study. Calprotectin concentrations were measured by an enzyme-linked immunosorbent assay in bile samples collected by endoscopic retrograde cholangiography from 106 PSC patients and 20 controls. Biliary calprotectin concentrations were compared between the 2 groups. In PSC patients, results were evaluated with regard to the presence of dominant bile duct stenoses, bile microbiology, MRS, survival free of liver transplantation, and necessity for bile duct interventions in the further disease course.Median (interquartile ranges) biliary calprotectin concentrations were higher in PSC patients than in controls (3646 ng/mL, 249–9748 vs 116 ng/mL, 104–655; P < 0.001). In the PSC cohort, higher biliary calprotectin concentrations were associated with the presence of microbes in bile (P = 0.02), the occurrence of dominant bile duct stenosis at any time in the disease course (P = 0.005), and the necessity for future bile duct interventions (P = 0.02). Patients with biliary calprotectin concentrations above a cut-off of 11,610 ng/mL displayed significantly shorter transplantation-free survival than those with biliary calprotectin concentrations ≤11,610 ng/mL (P < 0.001). Univariate Cox regression analysis revealed high biliary calprotectin concentration (>11,610 ng/mL) as a risk factor of shorter transplantation-free survival of PSC patients (P < 0.001) beside high plasma alkaline phosphatase (ALP) concentration (>142.5 U/L) (P = 0.006), high MRS (≥2) (P < 0.001), and nonsterility of bile (P = 0.03). Multivariate analysis identified only MRS (P = 0.002) and ALP concentration (P = 0.04) as independent risk factors.Our data strongly suggest that biliary calprotectin may be a valuable additional marker for disease activity and a predictor of outcome in PSC, so that further studies for evaluation of calprotectin in this disease are warranted.

show abstract

Section: Discussioncontrasting

confidence: 99%

Section: Discussionsupporting

confidence: 92%

Section: Discussionsupporting

confidence: 90%